Overview

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Status:
Not yet recruiting

Trial end date:
2030-12-23

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of nemtabrutinib compared to investigator's choice of fludarabine plus cyclophosphamide plus rituximab (FCR) or bendamustine plus rituximab (BR) in participants with previously untreated CLL/SLL without 17p deletion and/or tumor protein (TP) 53 mutation. The primary hypothesis is that nemtabrutinib is superior to FCR/BR with respect to progression-free survival (PFS).

Phase:

Phase 3

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Bendamustine Hydrochloride
Cyclophosphamide
Fludarabine
Rituximab